Ertapenem

Phase 2/3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

SURGICAL SITE INFECTION

Conditions

SURGICAL SITE INFECTION

Trial Timeline

Dec 1, 2010 → Oct 1, 2011

NCT ID

NCT01203046

About Ertapenem

Ertapenem is a phase 2/3 stage product being developed by Merck for SURGICAL SITE INFECTION. The current trial status is completed. This product is registered under clinical trial identifier NCT01203046. Target conditions include SURGICAL SITE INFECTION.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02041767	Approved	Completed	Dec 1, 2013	Jun 1, 2015	Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
NCT01159379	Approved	UNKNOWN	Jan 1, 2011	Dec 1, 2011	IgE-Mediated Hypersensitivity
NCT01203046	Phase 2/3	Completed	Dec 1, 2010	Oct 1, 2011	SURGICAL SITE INFECTION
NCT01173068	Pre-clinical	UNKNOWN	Aug 1, 2010	Sep 1, 2014	Urinary Tract Infections
NCT00939952	Approved	Completed	Jun 1, 2009	May 1, 2010	Continuous Ambulatory Peritoneal Dialysis

Competing Products

20 competing products in SURGICAL SITE INFECTION

See all competitors

Product	Company	Stage	Hype Score
Celecoxib	Astellas Pharma	Pre-clinical	23
Nivolumab + Everolimus	Ono Pharmaceutical	Phase 3	77
Epoetin alfa + Standard of Care	Johnson & Johnson	Approved	85
HR021618 + HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	52
SHR0410 Injection + Placebo for SHR0410 Injection	Jiangsu Hengrui Medicine	Phase 2	52
Ertapenem	Merck	Approved	85
Sugammadex + Rocuronium	Merck	Approved	85
Deep neuromuscular block	Merck	Approved	85
Rocuronium	Merck	Approved	85
Sugammadex + Neostigmine + Glycopyrrolate	Merck	Phase 3	77
Ecallantide + Placebo	Merck	Phase 2	52
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)	Novo Nordisk	Phase 1	32
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
parecoxib/valdecoxib	Pfizer	Approved	84
Tranexamic acid + Standard of Care	Pfizer	Approved	84
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + Placebo	Pfizer	Phase 3	76
valdecoxib + valdecoxib/placebo + placebo	Pfizer	Phase 3	76
PF-04531083 + PF-04531083 + Ibuprofen	Pfizer	Phase 2	51
Haemate HS	CSL	Phase 2	51
Fibrinogen Concentrate (Human) (FCH) + Placebo	CSL	Phase 3	76

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved